Clinical trial
STEPS Trial - Spheramine Safety and Efficacy Study
NCT00206687 · Bayer, Industry · Terminated
Key facts
| NCT number | NCT00206687 |
|---|---|
| Title | STEPS Trial - Spheramine Safety and Efficacy Study |
| Official title | Study of the Safety, Tolerability and Efficacy of Spheramine Implanted Bilaterally Into the Postcommissural Putamen of Patients With Advanced Parkinson's Disease |
| Lead sponsor | Bayer, Industry |
| Collaborators | Titan Pharmaceuticals Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson Disease |
| Intervention type | Biological, Procedure |
| Interventions | Spheramine (BAY86-5280), Placebo |
| Enrollment | 71 |
| Start date | Jan 8, 2003 |
| Primary completion | May 14, 2012 |
| Completion | May 14, 2012 |
| First posted | Sep 21, 2005 |
| Last update posted | Oct 31, 2024 |
| Countries | Germany, Spain, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: